Skip to main content
OpenTrials
Completed

NCT Number: NCT03698981

Reduce Stigma and Improve Treatment Adherence in HIV+ Pregnant Women

The goal of this proposal is to use a theoretically grounded approach to culturally-tailor a stigma intervention among just identified, pregnant HIV+ women in Botswana. This project will use empirically tested stigma interventions that have shown efficacy for serious mental illness and to adapt these to HIV. Additionally, a novel component of this intervention is the utilization of peers (i.e., mothers with HIV), which has been shown to be an effective stigma reduction agent for other conditions but has not yet been widely used with HIV.

The investigators propose to leverage this middle-income context to conduct a Randomized Controlled Trial (RCT) with HIV+ women (n=100 intervention group, n=100 control group). The investigators examine the stigma intervention for outcomes among mothers (including adherence to Antiretroviral therapy [ART] and antenatal treatment), and conduct exploratory birth outcomes among infants (e.g., birth weight, time of delivery) as well. Capacity building activities to transfer stigma intervention knowledge will occur throughout the project to enable investigators in Botswana to independently develop stigma interventions, thus serving as a model for other African countries. Finally, this pilot intervention will provide valuable data for future intervention trials to reduce stigma and improve ART adherence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Princess Marina Hospital IDCC

Gaborone, Botswana

About this study

To be completed by University of Botswana Research team:

The investigators will sample from the Dept. of Obstetrics and Gynecology (OB/GYN) at Princess Marina Hospital IDCC. Newly-diagnosed pregnant HIV+ women are referred to OB care at Ministry of Health (MOH) antenatal clinics and receive HIV care at the IDCC for continued ART. To account for expected drop out (~10%), ~220 participants will be recruited. All participants will be randomized to receive MME (the HIV-stigma intervention) or TAU (treatment as usual) from week 28-36 of their pregnancy. The investigators will initiate MME in the antenatal period because the cultural practice of botsetsi (below) could impede implementation post-partum. All participants will have PMTCT by initiation of ART before week 32. Adherence to ART, antenatal and PP care, and viral load testing will be tracked from week 28 of pregnancy to 16 weeks PP (~week 56 for full-term babies).

Procedures. To account for expected drop out (~10%), ~220 participants will be recruited, resulting in MME and TAU groups of ~100 with complete data at week 56. For the MME (intervention) arm, the investigators will enroll 9-10 women per group on a rolling basis to comprise ~12 intervention groups total; ~1 MME group will be initiated per month.

Intervention & Assessment Procedures. One advantage of our study is that, whenever possible, the investigators augment self-report measures with objective measures from medical records (i.e., for infants, birth-weights, APGAR scores at birth; for antenatal treatment, an Antenatal/delivery record tracking antenatal visits that is filled out by doctors; for ART, CD4 count and Viral load data from the integrated patient management system). Fidelity assessments for each session will be evaluated by Ho-Foster. Control Description: Control condition participants will receive TAU, including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the intervention group.

Follow-up Assessment (Months 18-22): Mothers' Postpartum (PP) adherence (56 weeks) serves as a key outcome. The investigators examine a set of exploratory, infant birth outcomes that may result from improved antenatal care and ART adherence. The investigators use an "Under 5 (years old) card" that is filled out by a doctor to track infant's developmental outcomes which is carried by the mother. Child outcomes include: APGAR score, preterm delivery, mortality (at <16 weeks), birthweight, vaccination record, and mother-to-child-transmission of HIV (MTCT). The investigators will call each participant at 4 months' time and ask to meet in person to review their "Under 5 card" to record infant outcomes at both: a) time of birth; b) 16 weeks PP.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • primiparous women
  • aged 18 to 45
  • diagnosed as HIV+
  • receiving care through IDCC with Botswana citizenship
  • speak either English or Setswana
  • able to provide informed consent

Exclusion criteria

  • unable to provide informed consent
  • non-English or Setswana speakers

Treatment and study plan

Mothers Moving towards Empowerment (MME)

Behavioral

MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a "good woman" and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children.

Primary outcomes

  1. Internalized Stigma

    Time frame: 7 minutes

    Assesses extent HIV stereotypes are applied to the self. 18 items. (scale 0-3). Good reliability & validity

  2. Anticipated Stigma

    Time frame: 4 minutes

    Assesses extent people living with HIV/AIDS (PLWHA) anticipate rejection if HIV disclosed. 10 items. (scale 0-3) Good reliability & validity

  3. Perceived Community Stigma

    Time frame: 8 minutes

    Assesses extent community members would devalue PLWHA. 20 items (scale: 0-3) Good reliability & validity

  4. Enacted Stigma

    Time frame: 10 minutes

    Experienced stigma by PWLHA. 28 items. (scale 0-3). Good reliability & validity

Secondary outcomes

  1. APGAR Score

    Time frame: 1minute

    Objective: 0-10 as rated by physician (documented at 5 minutes and 10 minutes)

  2. Pre-term delivery

    Time frame: 1minute

    Objective: Born prior to 37 weeks or 37 weeks and after (Yes/ No). Check hospital record

  3. Mortality

    Time frame: 1minute

    Objective: Mortality (e.g. neonatal, infant mortality) (Yes/No). Check hospital record

  4. Birthweight

    Time frame: 1minute

    Objective: Infant weight in grams (low = <2500 g or normal = >2500 g)

  5. Vaccinations

    Time frame: 1minute

    Objective: from 0-4 visits; Vaccines given at 0, 2, 3, and 4 months (e.g., BCG's, Hep B) (score: 0-3 months)

  6. Infant HIV status

    Time frame: 1minute

    PCR Assay conducted at 6 weeks and reflected in medical record; (Y/N)

Other outcomes

  1. Quality of Life Assessment scale

    Time frame: 16 minutes

    Self-report scale assessing quality of life. 42 items (scale 0-4). Good reliability & validity.

  2. Depressive Sx-CES-D

    Time frame: 8 minutes

    Self-report scale assessing depressive symptoms. 20 items (scale 0-3). Good reliability & validity

  3. Social Support

    Time frame: 16 minutes

    Self-report scale assessing functional social support. 40 items (scale 0-3). Good reliability & validity

Sponsors and collaborators

Lead sponsor

New York University

Other

Registry information

Official study title

Randomized Controlled Trial to Reduce Stigma and Improve Treatment Adherence in HIV+ Pregnant Women in Botswana

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Oct 9, 2018
Registry last updated
Mar 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.